A new research letter published yesterday in JAMA Network Open shows no new safety concerns or reactogenicity signals among babies and toddlers who received their first COVID-19 vaccines by the age of 2.

The research comes from 5,644 US children who received at least 1 dose of mRNA COVID-19 vaccine between the ages of 6 and 24 months. All of the children had mothers who received a COVID-19 vaccination 30 days before their last menstrual period or during pregnancy.

The mean age at first dose was 12.4 months. Twenty percent of the children included in the study received their COVID vaccine with at least one other vaccine administered at the same time. 

Postvaccination reactions were reported for 46.7% of children, with 21.1% and 38.8% experiencing local and systemic reactions, respectively, the authors said. Only 18 children in the study, 0.3%, experienced reactions described by participants as severe.

Fussiness most common reaction 

The most common reactions were fussiness (30%), local reaction (21.1%), and fever (13.8%). Six participants reported a seizure or febrile seizure after receiving COVID-19 vaccination. No deaths were reported.

Reactions were more common after the first dose of COVID vaccine than the second. 

This difference may reflect maternal vaccination; the first COVID-19 vaccination in our cohort may be some children’s second immunological encounter with a COVID-19 vaccine.

"This difference may reflect maternal vaccination; the first COVID-19 vaccination in our cohort may be some children’s second immunological encounter with a COVID-19 vaccine," the authors said. "These findings add evidence indicating that mild or moderate local and systemic reactions may be experienced, but severe reactions and serious adverse events are rare."

The US Department of Health and Human Services (HHS) Administration for Strategic Preparedness and Response (ASPR) yesterday announced two new investments worth more than $44 million to bolster the supply chain for essential medicines.

In a statement, ASPR said it will supply $32.4 million to Manus Bio, based in Waltham, Massachusetts, to expand its facilities to produce key starting materials for essential medicines. The company has a process for synthesizing chemicals into bioalternatives, including terpenoids, polyketides, phenylpropanoids, and flavonoids.

The new funding also provides $12 million to Antheia, a pharmaceutical ingredient maker in Menlo Park, California. ASPR said the company will focus on key starting materials and active pharmaceutical ingredients used to make essential medicines.

Dawn O'Connell, JD, Assistant Secretary for Preparedness and Response, said the investments help secure an important component of the US supply chain. "To make sure the medicines Americans need during national emergencies are available, we must continue our work to bring pharmaceutical manufacturing back to U.S. shores."

The Texas Department of State Health Services (TDSHS) yesterday announced the state's first locally acquired dengue case of the year, which involves a resident of Cameron County on the southern tip of the state on the border with Mexico.

Officials said that, amid a global surge in dengue activity, 106 travel-related cases, 1 of them fatal, have been reported among Texas residents. The state's imported cases are the most since 2002.

Since 2013, the state has recorded 665 dengue cases, including 40 reported locally from Cameron, Hidalgo, Starr, Val Verde, Webb, and Willacy counties. The TDSHS said mosquitoes remain active in much of Texas into November and December. It urged healthcare providers to consider and test for dengue in people who have symptoms of the virus, and it urged residents to take steps to avoid mosquito bites, such as wearing long sleeves and pants, applying insect repellent, and removing standing water.

Florida and California have also confirmed local dengue cases this year. Florida has reported 66 cases in 10 counties this year, most of them in Miami-Dade County. California has reported 15 cases in Los Angeles, San Diego, and San Bernardino counties. 

New research comparing 2019 and 2021 National Inpatient Sample (NIS) Databases from the Healthcare Cost and Utilization Project shows pediatric hospital admissions were reduced by 17.2% because of pandemic closures or allocations of pediatric beds to adult care.

The number of hospitals with at least 1 non-neonatal pediatric admission declined by 374 across the country, the authors said in a research letter in JAMA Network Open.. Almost half of this decline (181 of 374 hospitals [48.4%]) was in hospitals with more than 60% of admissions among Medicaid patients, the authors said. 

During the first weeks of the pandemic, children’s hospital beds were allocated to adults, as school closures limited common childhood illnesses and children mostly did not suffer from severe COVID-19 infections. 

Compared with 2019, in 2021 the largest proportional declines were in pediatric hospitals that were private, investor owned (297 to 217 [−26.9%]); small (748 to 570 [−23.8%]); or urban, nonteaching (411 to 276 [−32.8%]).
 

Now is the time to reverse course

"Rapid, uncontrolled closure of pediatric hospital services presents a public health challenge,” the authors said. “While some closed pediatric inpatient services may reopen, history and system dynamics suggest that most will become permanent casualties of the pandemic. If so, access to care among vulnerable rural and Medicaid populations will be especially affected.”

In a commentary on the study, Matthew Davis, MD, of Nemours Children’s Health in Wilmington, Delaware, said the time is now to correct the course of pediatric hospital closures. 

Now is the time to develop a national plan for sizing and sustaining pediatric hospital services to meet the child health–driven need for such services

"Now is the time to develop a national plan for sizing and sustaining pediatric hospital services to meet the child health–driven need for such services," he wrote. "There is an opportunity in the wake of the COVID-19 pandemic and in the context of multiple pressures on institutions with pediatric inpatient services to ensure access for children to subspecialty-enabled hospital capabilities as needed."

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and the Clinton Health Access Initiative (CHAI) announced today that they are teaming up to explore interventions to slow the spread of gonorrhea in low- and middle-income countries (LMIC).

The 2-year partnership between CARB-X and CHAI will evaluate the clinical need and address market barriers for diagnostic, therapeutic, and preventive interventions for gonorrhea, which is the second most prevalent sexually transmitted infection in the world. An estimated 82 million gonorrhea infections are reported annually, with the highest prevalence in Africa. 

Focus on antibiotic-resistant gonorrhea

The work will focus on antibiotic-resistant gonorrhea, which has become increasingly common in LMICs. Neisseria gonorrhoeae (the bacterium that causes gonorrhea) has become resistant to every antibiotic that's been used for treatment, and currently has one remaining effective treatment option (ceftriaxone). Untreated gonorrhea can result in a host of serious side effects, including pelvic inflammatory disease and infertility.

The effort will start with a clinical needs assessment in eight LMICs. Using surveys and focused interviews, CARB-X and CHAI hope to develop a better understanding of which solutions should be prioritized, how market barriers might limit implementation of those solutions, and how access can be expanded.

Since CARB-X was founded in 2016, diagnostics, vaccines, and therapeutics for antibiotic-resistant gonorrhea have been among its funding priorities. In June, the group announced an award of $1 million to Prompt Diagnostics LLC to develop a rapid, low-cost, portable diagnostic test for drug-resistant gonorrhea.

"We are excited to embark on this initial body of work with CHAI, leveraging their experience in market assessment and thoughtful implementation of interventions for HIV and other STIs in LMICs over the past 20 years," CARB-X Chief of R&D Erin Duffy, PhD, said in a press release. "Our goal is to build off work done by others in this space, such as FIND and the Global Antibiotic Research & Development Partnership (GARDP) and share our learnings broadly so that all entities working toward gonorrhea-focused interventions can provide meaningful solutions where they are needed the most."

An online survey of physicians in the United States, France, and Germany reveals that they consider pertussis (whooping cough) vaccines less important than those against COVID-19, influenza, and pneumococcal disease, although they recognize that adults with weakened immune systems and chronic respiratory illnesses are at elevated risk.

For the study, published today in BMC Primary Care, a team led by researchers from the University of Pittsburgh and vaccine developer Sanofi surveyed 400 US physicians and 200 each in France and Germany from November 2022 to January 2023. The respondents were listed in an independent database of physicians who indicated an interest in participating in research.

"Pertussis is a highly contagious respiratory tract infection that affects all ages, though it is most severe in young infants," the authors wrote. "Adults, especially those with respiratory conditions or other chronic illnesses can also suffer serious consequences of pertussis."

Attitudes similar pre-, post-pandemic

In total, 65% of respondents indicated that universal vaccination against pertussis is important, a lower percentage than for vaccination against COVID-19 (82%), flu (81%), pneumococcal disease (76%), and tetanus (73%). The results were similar by country and before and after the COVID-19 pandemic.

Physicians recognized the need to immunize vulnerable adults who are at risk of severe pertussis ... but this awareness frequently did not result in vaccination of these priority groups, especially without official recommendations.

Physicians recognized that adults with weakened immune systems, chronic obstructive pulmonary disease (COPD), asthma, and other respiratory diseases were at high risk from pertussis.

Respondents estimated that of the adults for whom they recommend the pertussis vaccine, two-thirds agree to receive it but said a common reason for not following through with vaccination was the perception of low personal risk.

Most surveyed physicians (76%) said that adult pertussis vaccination uptake is suboptimal and agreed on the importance of protecting vulnerable people against pertussis by vaccinating the person (77%) or their close contacts (78%).

"Physicians recognized the need to immunize vulnerable adults who are at risk of severe pertussis, such as those with asthma and/or COPD, but this awareness frequently did not result in vaccination of these priority groups, especially without official recommendations to support such vaccination in these groups," the researchers wrote.